Register Now & Save up to $500

August 20-22, 2018 | San Francisco, CA

www.ipf-summit.com

2nd Annual IPF Summit 2018

Overcome Translational Challenges in the Development of Truly Curative IPF Drugs

18 Expert Speakers Include:

Gerald Nabozny
Executive Director
Inflammation Immunology & Respiratory Diseases Research
Boehringer Ingelheim

Joe Arron
Senior Director
Immunology Research
Genentech

Fernando Martinez
Executive Vice Chair of Medicine
Weill Cornell Medical College

Timothy Blackwell
Professor of Cell & Developmental Biology
Vanderbilt University Medical Center

Jan De Backer
Chief Executive Officer
FLUIDDA

"Recent ground-breaking research and clinical developments in IPF highlight how rapidly this field is moving forward. Don't miss out on this cutting-edge IPF meeting"
Cory Hogaboam, Professor of Medicine, Cedars-Sinai Medical Center

Program Partner

FLUIDDA

Tel: +1 415 735 3289 **Email:** Info@hansonwade.com
www.ipf-summit.com

hansonwade

Welcome to the 2nd IPF Summit

Confidently & Robustly Utilize Preclinical Models Beyond Bleomycin, Understand Mechanisms of Action of Emerging Therapeutics & Leverage Human Genetics to Optimize Patient Stratification in Clinical Trials

The **2nd IPF Summit** is the IPF industry definitive discussion and networking forum, helping drug developers to **solve the translational gap between limited preclinical predictability and corresponding clinical attrition.**

Built with **Boehringer Ingelheim, Bristol Myers Squibb** and **Celgene**, this intimate summit will pre-competitively advance the field beyond empirical data and more confidently translate IPF candidates through drug development pipelines.

Join your drug developer peers to:

- Analyze preclinical results beyond bleomycin to understand the value of different platform modalities and more confidently assess your candidate *in vivo* and *in vitro*
- Navigate the rationale and successes so far of combination therapy decisions to inform phase 3 clinical trial design
- Understand the mechanisms of action of successful candidates in the clinic and novel emerging therapeutics targeting fibrosis reversal to influence your own pipeline decisions

You'll leave this highly focused IPF forum equipped with the knowledge and connections to advance your next 12 months of IPF therapeutic research.

What attendees of IPF Summit 2017 had to say:

"Speed networking and round table discussions were great"
Biogen

"This disease specific conference was informative - by planning a concentrated topic it gave an opportunity to look through a tighter lens"
Genentech

"All the speakers were superb, and every session provided novel and important insight regarding IPF. The effort the speakers put into their presentations was evident. Great job!"
Ceders-Sinai Medical Center

Top 5 Reasons to Attend the 2nd IPF Summit

1.

Better inform next generation therapeutic decisions by understanding and analyzing hypotheses surrounding epithelial cells and the aberrant regenerative mechanisms characterizing IPF with Ceders-Sinai

2.

Investigate mechanisms of action of emerging therapeutics and **understand the progress of leading phase 2 clinical candidates** with Kadmon, Prometic Life Sciences and Promedior

3.

Navigate combination therapeutics as potential therapeutic collaborations and to **inform phase 3 trial design** with Genentech, Nitto BioPharma, and FibroGen

4.

Evaluate genetic mechanisms with IPF through next generation sequencing data to **advance understanding of patient stratification** with Vanderbilt University

5.

Outline the potential and added value of imaging techniques to inform **biomarker identification, clinical endpoints and enrichment of clinical trial populations** with FLUIDDA

18 Expert Speakers

Anne Phelan
Senior Vice President & Head of Discovery Research
Mission Therapeutics

Brian Windsor
Chief Executive Officer
Lung Therapeutics

Cory Hogaboam
Professor of Medicine
Ceders-Sinai Medical Center

David Schwartz
Professor of Medicine & Immunology
University of Colorado-Denver

Fernando Martinez
Executive Vice Chair of Medicine
Weill Cornell Medical College

Gerald Nabozny
Executive Director Inflammation, Immunology & Respiratory Diseases Research
Boehringer Ingelheim

Jan De Backer
Chief Executive Officer
FLUIDDA

Joe Arron
Senior Director Immunology Research
Genentech

John Moran
Chief Medical Officer
Prometic Life Sciences

John Ryan
Executive Vice President & Chief Medical Officer
Kadmon

Jonathan Kropski
Assistant Professor of Medicine
Vanderbilt University Medical Center

Majd Mouded
Medical Director
Biogen

Mary Salvatore
Associate Professor of Radiology
Mount Sinai Medical Center

Rick Jack
President, Chief Operations Officer & Chief Scientific Officer
Promedior

Rusty Montgomery
Director, Research
miRagen Therapeutics

Seth Porter
Vice President Fibrosis Therapeutics
FibroGen

Timothy Blackwell
Professor of Cell & Developmental Biology
Vanderbilt University Medical Center

Ulrike Muscha Steckelings
Chief Scientific Officer
Vicore Pharma

Wenbin Ying
Executive Vice President
Nitto BioPharma

"The first IPF summit was extremely successful. It allowed for industry and academics to interact over discussions of pathogenesis, biomarkers and clinical trial challenges. As the field continues to evolve, this forum is increasingly important to continue to facilitate those discussions"
Majd Mouded, Medical Director, Biogen

Conference Day One | Tuesday, August 21

Fernando Martinez
Executive Vice Chair of Medicine
Weill Cornell Medical College

8.50 **Chair's Opening Remarks**

IPF: Recent Advances & the Future Landscape

Fernando Martinez
Executive Vice Chair of Medicine
Weill Cornell Medical College

9.00 **Keynote: "IPF: Where are we now?"**
- Highlighting progress from IPF Summit 2017 including advancement of the standardization of imaging
- Reviewing the IPF drug development landscape
- Outlining outcomes for the 2nd IPF Summit from the outset

Beyond Bleomycin: More Confidently Utilizing Preclinical Models

Gerald Nabozny
Executive Director, Inflammation, Immunology & Respiratory Diseases Research
Boehringer Ingelheim

9.30 **Beyond Bleomycin: The Nintedanib Experience**
- Exploring the mode of action of Nintedanib using a broad and diverse set of cellular models
- Discussing *in vivo* models with diverse triggers
- Sharing what was learned about Nintedanib activity in preclinical models

10.00 **Speed Networking**
This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the IPF field and establish meaningful business relationships to pursue for the rest of the conference.

10.45 **Morning Refreshments**

Targeting Translational Failings Through Use of Non-Invasive Imaging & Biomarkers

Jan De Backer
Chief Executive Officer
FLUIDDA

11.45 **Regional Disease Progression & Quantification of Interstitial Lung Diseases Using Functional Respiratory Imaging**
- Outlining Functional Respiratory Imaging for use in IPF
- Demonstrating the value of quantitative CT imaging in IPF drug development
- Highlighting imaging use to show regional disease state and expression
- Discussing imaging associated biomarkers within IPF

Majd Mouded
Medical Director
Biogen

12.15 **Leveraging Biomarker Data for Dose Selection**
- Outlining biomarker selection in IPF and associations with the TGFβ pathway
- Showcasing preclinical data outlining doses to inhibit fibrosis in animal models
- Analyzing human studies at 8 weeks for extent of TGFβ inhibition and rationale behind dose selection

12.45 **Lunch & Networking**

Next Generation of IPF Clinical Trials: Evaluating Trial Design

John Moran
Chief Medical Officer
Prometic Life Sciences

1.45 **IPF: An Orphan Disease with Successful Phase 3 Trials!**
- Overcoming the challenges of designing a phase 3 trial with limited prior trial data in an orphan disease
- Good news: For IPF we have a legion of data from pivotal phase 3 studies
- Bad news: For IPF there are two approved drugs

2.15 **Think Tank Round Table Discussions: What Does the Next Generation of Phase 3 Clinical Trials Look Like?**

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics, debate best practice and share experiences to identify solutions.

1. What benefits will payers need to see to consider a new therapeutic & how do we design clinical trials to best demonstrate these?

2. Can imaging be accepted as a secondary endpoint?

3. How do we get predictive reads of efficacy with smaller sample sets to then draw predictions for large sample sizes?

4. How do we overcome an adverse safety profile from a standard of care when running phase 3 trials for a new candidate?

2.45 **Moderator Feedback & Audience Debate**

Moderators will be assigned to each roundtable to facilitate discussion and collate the findings.
Following the roundtables, they will present back to the entire delegation as part of information dissemination and opening up the wider audience debate.

3.15 **Afternoon Refreshments & Networking**

John Ryan
Executive Vice President & Chief Medical Officer
Kadmon

4.15 **Rho-Associated Coiled-Coil Kinase 2 (ROCK2) Inhibition in IPF**
- Outlining therapeutic potential of ROCK inhibition in regulating pro-fibrotic processes
- Sharing the ongoing clinical development of KD025 in IPF

Taking Advantage of Human Genetics for Preclinical & Clinical Decisions

David Schwartz
Professor of Medicine & Immunology
University of Colorado-Denver

4.45 **Genetic & Genomic Considerations in IPF Clinical Trials**
- Outlining IPF as a heterogeneous disease caused by multiple gene variants
- Demonstrating the distinct clinical course for each type of IPF
- Showing how drug trials should control the disease heterogeneity in IPF

Timothy Blackwell
Professor of Cell & Developmental Biology
Vanderbilt University Medical Center

Fernando Martinez
Executive Vice Chair of Medicine
Weill Cornell Medical College

David Schwartz
Professor of Medicine & Immunology
University of Colorado-Denver

5.15 **Panel Discussion: Precision Medicine in IPF - Using Genetics to Inform Patient Stratification Decisions for Clinical Trials**

Shared insights from key opinion leaders with a focus on:

- Outlining what is known about inherited genetic factors and their influence in the development of IPF
- Hypothesizing how future studies will characterize patient phenotypes and how they will influence trial design and outcome
- Understanding the influence of genetics and precision therapeutics on clinical decision-making regarding IPF diagnosis and treatment

Fernando Martinez
Executive Vice Chair of Medicine
Weill Cornell Medical College

5.45 **Chair's Closing Remarks**

6.00 **Scientific Poster Session**

After the formal presentations have finished, the learning and networking carries on. The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.

"This summit was extremely valuable and a great showcase of the current trends and thinking in the area of IPF"
AdAlta

"Overall I thought very highly of the conference and the job Hanson Wade did as an organizer. Great speakers, lots of useful information, very timely. Top key opinion leaders in the field"
Lung Therapeutics

"Great meeting"
Actelion Pharmaceuticals

Conference Day Two | Wednesday, August 22

Fernando Martinez
Executive Vice Chair of Medicine
Weill Cornell Medical College

8.50 **Chair's Opening Remarks**

Identifying the "Idiopathic" of IPF to Drive Curative IPF Drug Development

Cory Hogaboam
Professor of Medicine
Ceders-Sinai Medical Center

9.00 **Translational Modeling of Profibrotic & Aberrant Regenerative Mechanisms in IPF**

- Dissecting the pathology of IPF as a disease of enhanced fibrosis and impaired lung regeneration
- Proving how translational modeling in humanized immunodeficient mice facilitates exploration of both mechanisms in IPF
- Describing putative therapeutic strategies that target both fibrosis and lung regeneration

Outside of Targeting Fibroblasts: Therapeutically Promoting Regeneration

Brian Windsor
Chief Executive Officer
Lung Therapeutics

9.30 **Restoring Balance in IPF: Development of a Compound Targeting Both Epithelial Cell Survival as well as Myofibroblast Destruction for Improved Therapeutic Response**

- Outlining a novel approach beyond inhibition of fibroblast activation
- Demonstrating the Cav1 pathway as allowing for restoring survival signals that have become dysregulated in IPF
- Discussing the preservation of epithelial cell survival as critical in enabling restoration of lung function

10.00 **Morning Refreshments & Networking**

Rusty Montgomery
Director, Research
miRagen Therapeutics

11.00 **Innovative RNA Based Therapeutics as a Modality for the Effective Treatment of Multiple Fibrotic Conditions**

- Understanding miRNAs as regulators of systems biology
- Outlining miR-29 as an anti-fibrotic miRNA
- Showing miR-29 as a therapeutic target in multiple fibrotic indications
- Presenting the development of an inhaled oligonucleotide

Wenbin Ying
Executive Vice President
Nitto BioPharma

11.30 **Developmental Program Identifying siRNA HSP47 as a New Therapeutic Strategy for IPF – Comprehensive Model Validation & Therapeutic Evaluation**

- Highlighting new target engaged in fibrotic disease development and progress
- Demonstrating novel lipid nanoparticle for *in vivo* siRNA delivery which show robust anti-fibrotic activities
- Outlining results of efficacy tested in the fully validated bleomycin rat model in the clinically relevant scenario and treatment regimen
- Showing results from pulmonary function assessment included in the therapeutically efficacy evaluation

12.00 **Lunch & Networking**

Navigating the Rationale, Practical & Clinical Success of Combination Therapies

Joe Arron
Senior Director, Immunology Research
Genentech

1.00 **Lessons Learnt from Combination Therapies with Pirfenidone**

- Outlining rationale from combinations of pirfenidone in clinical trials with two new interventions
- Analyzing decisions made
- Benchmarking lessons learnt

Seth Porter
Vice President
Fibrosis Therapeutics
FibroGen

Joe Arron
Senior Director
Immunology
Research
Genentech

John Moran
Chief Medical Officer
Prometic Life Sciences

1.30 **Panel Discussion: Assessing the Current Drug Landscape to Understand Combinations as Successful Treatment Options Within IPF**

- Beyond IPF – is there potential for combinations with candidate targeting other disease areas, such as lung cancer?
- Addressing tolerability and dosage concerns when drugs are given in combination in the context of an IPF patient
- What is the future of IPF in terms of product development?

Robustly & More Confidently Moving Through Clinical Development: Showcasing & Analyzing Results

Ulrike Muscha Steckelings
Chief Scientific
Officer
Vicore Pharma

2.00 **Targeting the Angiotensin AT2-receptor for the Treatment of Orphan Fibrotic Diseases**

- Describing the biology of the angiotensin AT2-receptor
- Understanding the anti-fibrotic mechanism of action of the AT2-receptor agonist C21
- Detailing the clinical development of C21

2.30 **Afternoon Refreshments & Networking**

Anne Phelan
Senior Vice President
& Head of Discovery
Research
Mission Therapeutics

3.30 **UCHL1 – A Deubiquitylating Enzyme with Fundamental Roles in the Regulation of Pro-Fibrotic Signalling Pathways**

- Highlighting the key role of deubiquitylating enzymes in the regulation of protein homeostasis, complex formation and turnover or degradation
- Outlining how UCHL1 is recognized as a key modulator of components of the TGFβ, AKT and ERK pro-fibrotic signalling cascades across a range of tissue types
- Demonstrating how the expression of UCHL1 has been shown to be upregulated in lung samples derived from patients with IPF and COPD; and that UCHL1 gain-of-function polymorphism is associated with Akt mediated lung fibrosis pathologies and PAH
    - Sharing the clinical potential of a potent and selective inhibitor of UCHL1 in the treatment of fibrotic lung diseases

Rick Jack
President, Chief
Operations Officer
& Chief Scientific
Officer
Promedior

4.00 **Evaluation of Pentraxin-2 (PRM-151) in IPF Clinical Trial Settings**

- Overcoming challenges in the translational steps between discovery and phase 2 Clinical Trial
- Linking phase 1 design and results with phase 2 design
- Translating PRM-151 into the clinic: how non-clinical and clinical data from IPF clinical trials can guide other fibrosis therapeutic applications

Fernando Martinez
Executive Vice Chair
of Medicine
Weill Cornell Medical College

4.30 **Chair's Closing Remarks**

Pre-Conference Workshop Day | Monday, August 20

Morning Workshop A

Adding Radiology to the Pulmonary Fibrosis Equation

9:00am – 12:00pm

Advancements in the application of imaging techniques such as quantitative HRCT to inform and enrich clinical trials decisions undoubtedly goes hand-in-hand with the next generation of IPF drug development. Leveraging imaging's capacity to advance biomarker identification, endpoint design and patient identification is now pivotal in advancing clinical translation and drug trial success.

Join your peers to discuss and evaluate:

- Implementing HRCT as a means of early diagnosis of lung fibrosis for better insight into patient outcomes
- Utilizing HRCT for the correct diagnosis of IPF lung fibrosis against other ILD fibrosis to more confidently achieve correct diagnosis and better inform further clinical decisions
- Demonstrating the use of HRCT as a surrogate biomarker of lung fibrosis to evaluate treatment response during drug development

Workshop Leader

Mary Salvatore
Associate Professor of Radiology
Mount Sinai Medical Center

Afternoon Workshop B

Using Genetic Information to Personalize Therapeutic Approaches for IPF

1:00pm – 4:00pm

Poor prognosis, varying and unpredictable rates of progression despite treatment, and increasing population size means that the need for truly disease modifying IPF candidates is increasing. Is the answer precision therapy? Harnessing an improved understanding of the genetic mechanisms driving IPF pathologies could offer insights into next generation, better clinical outcomes.

Be part of the discussion at this workshop on:

- Using the at-risk phenotype to identify the early IPF phenotype
- Evaluating rare genetic variants associated with IPF in both familial and sporadic cases, including telomerase and surfactant protein pathway mutations
- Comparing rare variants with common variants as drivers within the IPF population, utility of next generation sequencing

Workshop Leaders

Timothy Blackwell
Professor of Cell & Developmental Biology
Vanderbilt University Medical Center

Jonathan Kropski
Assistant Professor of Medicine
Vanderbilt University Medical Center

Partnership Opportunities

Why Partner?

From extensive research with over 20 IPF stakeholders including Celgene, GlaxoSmithKline, Bristol Myers Squibb and Genentech we've been told drug developers are actively seeking solutions to confidently and more robustly overcome the translational gap between preclinical predictability and clinical attrition.

Partnering with the **2nd IPF Summit** is your opportunity to **elevate your company's innovations to a targeted audience of IPF pharma and biotech**. Your brand, your message, your reputation – showcased in front of the leading minds in IPF drug development.

Whether you're on the brink of validating your technology and need to communicate this exciting progress to the field, or you're simply looking to establish new business connections, put names to faces, or understand the progressions shaping the field: we can help you find the right solution.

Find out how we can support your 2018/19 business objectives and help you achieve your goals faster.

Contact us today at **sponsor@hansonwade.com**

Attending Seniority Breakdown from the IPF Summit 2017



*Based on IPF Summit 2017 statistics

Attending Companies Breakdown from the IPF Summit 2017



*Based on IPF Summit 2017 statistics

FLUIDDA

Program Partner

FLUIDDA is active in the field of Functional Respiratory Imaging (FRI) research and development. The company's proprietary FRI technology offers pharmaceutical companies and healthcare providers a unique entry point into drug development strategies for patients suffering from respiratory diseases such as Idiopathic Pulmonary Fibrosis. Implementation of FRI in the clinical practice creates significant added value to the current healthcare standard in the respiratory field.

www.fluidda.com

Become a Partner

Jakub Nunuk
Partnership Manager
T: +1 617 455 4188
E: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.ipf-summit.com/register/

Tel: +1 415 735 3289

Email: register@hansonwade.com

1. Investigate mechanisms of action of emerging therapeutics to inform your own novel candidate decisions
2. More confidently & robustly overcome translational challenges from preclinical predictability into the clinic
3. Evaluate genetic mechanisms within IPF to advance understanding of the stratification of the IPF population & enrich clinical trials

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: **register@hansonwade.com**

Secure Your Place

Package Details	Register & Pay before **Friday May 18, 2018**	Register & Pay before **Friday June 15, 2018**	Register & Pay before **Friday July 13, 2018**	Standard Prices
GOLD Conference + 2 Workshops	$3697 **(save $500)**	$3797 **(save $400)**	$3897 **(save $300)**	$3997 **(save $200)**
SILVER Conference + 1 Workshop	$3098 **(save $400)**	$3198 **(save $300)**	$3298 **(save $200)**	$3398 **(save $100)**
BRONZE Conference Only	$2499 **(save $300)**	$2599 **(save $200)**	$2699 **(save $100)**	$2799
Workshops (Each)	$699			

*Special 40% off for academics available upon request





VENUE

The Marker
501 Geary Street, San Francisco
CA 94102, United States

For further information or assistance, please visit www.jdvhotels.com